Cargando…
Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells
eEF-2K has important roles in stress responses and cellular metabolism. We report here a previously unappreciated but critical role of eEF-2K in regulating the fate and cytocidal activity of CD8(+) T cells. CD8(+) T cells from eEF-2K KO mice were more proliferative but had lower survival than their...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809536/ https://www.ncbi.nlm.nih.gov/pubmed/35108044 http://dx.doi.org/10.1126/sciadv.abl9783 |
_version_ | 1784644036873682944 |
---|---|
author | Das, Jugal Kishore Ren, Yijie Kumar, Anil Peng, Hao-Yun Wang, Liqing Xiong, Xiaofang Alaniz, Robert C. de Figueiredo, Paul Ren, Xingcong Liu, Xiaoqi Ryazonov, Alexey G. Yang, Jin-Ming Song, Jianxun |
author_facet | Das, Jugal Kishore Ren, Yijie Kumar, Anil Peng, Hao-Yun Wang, Liqing Xiong, Xiaofang Alaniz, Robert C. de Figueiredo, Paul Ren, Xingcong Liu, Xiaoqi Ryazonov, Alexey G. Yang, Jin-Ming Song, Jianxun |
author_sort | Das, Jugal Kishore |
collection | PubMed |
description | eEF-2K has important roles in stress responses and cellular metabolism. We report here a previously unappreciated but critical role of eEF-2K in regulating the fate and cytocidal activity of CD8(+) T cells. CD8(+) T cells from eEF-2K KO mice were more proliferative but had lower survival than their wild-type counterparts after their activation, followed by occurrence of premature senescence and exhaustion. eEF-2K KO CD8(+) T cells were more metabolically active and showed hyperactivation of the Akt-mTOR-S6K pathway. Loss of eEF-2K substantially impaired the activity of CD8(+) T cells. Furthermore, the antitumor efficacy and tumor infiltration of the CAR-CD8(+) T cells lacking eEF-2K were notably reduced as compared to the control CAR-CD8(+) T cells. Thus, eEF-2K is critically required for sustaining the viability and function of cytotoxic CD8(+) T cells, and therapeutic augmentation of this kinase may be exploited as a novel approach to reinforcing CAR-T therapy against cancer. |
format | Online Article Text |
id | pubmed-8809536 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-88095362022-02-16 Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells Das, Jugal Kishore Ren, Yijie Kumar, Anil Peng, Hao-Yun Wang, Liqing Xiong, Xiaofang Alaniz, Robert C. de Figueiredo, Paul Ren, Xingcong Liu, Xiaoqi Ryazonov, Alexey G. Yang, Jin-Ming Song, Jianxun Sci Adv Biomedicine and Life Sciences eEF-2K has important roles in stress responses and cellular metabolism. We report here a previously unappreciated but critical role of eEF-2K in regulating the fate and cytocidal activity of CD8(+) T cells. CD8(+) T cells from eEF-2K KO mice were more proliferative but had lower survival than their wild-type counterparts after their activation, followed by occurrence of premature senescence and exhaustion. eEF-2K KO CD8(+) T cells were more metabolically active and showed hyperactivation of the Akt-mTOR-S6K pathway. Loss of eEF-2K substantially impaired the activity of CD8(+) T cells. Furthermore, the antitumor efficacy and tumor infiltration of the CAR-CD8(+) T cells lacking eEF-2K were notably reduced as compared to the control CAR-CD8(+) T cells. Thus, eEF-2K is critically required for sustaining the viability and function of cytotoxic CD8(+) T cells, and therapeutic augmentation of this kinase may be exploited as a novel approach to reinforcing CAR-T therapy against cancer. American Association for the Advancement of Science 2022-02-02 /pmc/articles/PMC8809536/ /pubmed/35108044 http://dx.doi.org/10.1126/sciadv.abl9783 Text en Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Biomedicine and Life Sciences Das, Jugal Kishore Ren, Yijie Kumar, Anil Peng, Hao-Yun Wang, Liqing Xiong, Xiaofang Alaniz, Robert C. de Figueiredo, Paul Ren, Xingcong Liu, Xiaoqi Ryazonov, Alexey G. Yang, Jin-Ming Song, Jianxun Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells |
title | Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells |
title_full | Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells |
title_fullStr | Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells |
title_full_unstemmed | Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells |
title_short | Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells |
title_sort | elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of cd8(+) t cells |
topic | Biomedicine and Life Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809536/ https://www.ncbi.nlm.nih.gov/pubmed/35108044 http://dx.doi.org/10.1126/sciadv.abl9783 |
work_keys_str_mv | AT dasjugalkishore elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells AT renyijie elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells AT kumaranil elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells AT penghaoyun elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells AT wangliqing elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells AT xiongxiaofang elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells AT alanizrobertc elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells AT defigueiredopaul elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells AT renxingcong elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells AT liuxiaoqi elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells AT ryazonovalexeyg elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells AT yangjinming elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells AT songjianxun elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells |